RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
  Dialysis
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Editorial
Nephrology Channel

subscribe to Nephrology newsletter
Latest Research : Nephrology

   EMAIL   |   PRINT
AVOID study shows Aliskiren decreasing albuminuria

Jun 12, 2008 - 11:35:31 AM , Reviewed by: Dr. Sanjukta Acharya

 
[RxPG] The much awaited results of the AVOID (Aliskiren in the eValuation of prOteinuria In Diabetes) study were published in the June 5th edition of the New England Journal of Medicine. It is the first study which looked at the kidney-protective benefits of Aliskiren, independent of its proven blood pressure reductions.

About the study
The AVOID study is one of the trials in the landmark ASPIRE HIGHER clinical trial program, the largest ongoing cardio-renal outcomes program involving more than 35,000 patients in 14 trials. The ASPIRE HIGHER program is studying the effect of direct renin inhibition in a variety of cardiac and renal conditions.

Mechanism of action
Aliskiren is an oral renin inhibitor. Renin is secreted by the kidney in response to decreases in blood volume and low renal perfusion. Renin cleaves the peptide angiotensinogen to the inactive decapeptide angiotensin I. Angiotensin I is converted to the active octapeptide angiotensin II by angiotensin-converting enzyme (ACE) produced in the lungs. Angiotensin II is a vasoconstrictor and also promotes aldosterone secretion and sodium reabsorption, which increases blood pressure. It provides a negative feedback to decrease the production of renin. This cycle is known as the renin-angiotensin-aldosterone system. Thus, as a direct renin inhibitor, aliskiren disrupts the RAAS process by decreasing plasma renin activity (PRA).

Method and findings
599 patients were involved in this multinational, randomized, double-blind study. Initially all patients received 100 mg of losartan daily and then they were randomly assigned to receive 6 months of treatment with aliskiren (initially 150 mg and then increased to 300 mg) or placebo, in addition to losartan. The primary outcome seen was a reduction in albuminuria by an additional 20% in type 2 diabetic patients with kidney disease who also had a diagnosis of high blood pressure. These patients were already taking the maximum dose of the angiotensin-receptor blocker (ARB) losartan.As far as side effects were concerned, hyperkalemia reported as an adverse event was seen in 5% of patients taking Aliskiren in addition to losartan, compared to 5.7% of those taking placebo plus losartan. Hyperkalemia as a laboratory abnormality was seen in 13.7% of patients on aliskiren and losartan, compared to 10.8% of the patients taking placebo and losartan.

It, therefore, appears that aliskiren in addition to optimising blood pressure treatment, has additional benefits. But whether a decrease in albuminuria will translate into slowing the decline of renal function is still to be seen . Perhaps, the ALTITUDE study, which is planning to enroll 8500 patients in 36 countries and is due to report results in 2011, will provide the answer.



Publication: NEJM 5th June 2008

Advertise in this space for $10 per month. Contact us today.


Related Nephrology News
Renal biomarkers predict risk of acute kidney injury following surgery in two large studies
Intradialytic hypotension associated with increased incidence of haemodialysis vascular access thrombosis
Mouse model shows that kidney-specific dopamine system important for kidney function and blood pressure regulation
Blood pressure control system in distal nephron
Adherence to cardiac medication less in renal patients
Higher Leptin levels associated with lower bone turnover in Renal transplant patients
Vegetarian diets help renal patients to lower serum phosphorus and FGF-23 levels
SHARP trial shows benefit of cholesterol-lowering in Chronic Kidney Patients
Low Phosphate diet not helpful in dialysis patients
Poor kidney function in HIV- infected drug users

Subscribe to Nephrology Newsletter

Enter your email address:


 About Dr. Sanjukta Acharya
This news story has been reviewed by Dr. Sanjukta Acharya before its publication on RxPG News website. Dr. Sanjukta Acharya, MBBS MRCP is the chief editor for RxPG News website. She oversees all the medical news submissions and manages the medicine section of the website. She has a special interest in diabetes and endocrinology. She can be reached for corrections and feedback at sanjukta.acharya@rxpgnews.com
RxPG News is committed to promotion and implementation of Evidence Based Medical Journalism in all channels of mass media including internet.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)